Breadcrumbs

University of Waikato study finds inequities in bowel cancer treatment

21 August 2020

Cancer treatment

A University of Waikato study published in the New Zealand Medical Journal looking at the treatment and timeliness of chemotherapy for bowel cancer patients in New Zealand has found there are inequities in the treatment of Pacific, Māori and Asian patients.

The study, led by Professor of Population Health, Ross Lawrenson, looked at data from New Zealand’s cancer and pharmaceutical databases between 2006-2016 across more than 30,000 bowel cancer (colon and rectal cancer) patients.

The findings will inform the newly-established New Zealand Cancer Control Agency, responsible for delivering equitable and nationally consistent cancer services for all New Zealanders.

Although the treatment and timeliness of chemotherapy for bowel cancer has been improving, Professor Lawrenson says there were disparities found particularly among Pacific and Māori patients in the use of chemotherapy for patients with colon cancer. In particular:

Pacific patients

  • 53% less likely to be given chemotherapy treatment for colon cancer.

Māori patients

  • 37% less likely to be given chemotherapy treatment for colon cancer.

Asian patients

  • 31% less likely to be given timely chemotherapy treatment for colon cancer.

In addition, patients in the Southern Cancer Region, which includes Nelson/Marlborough, Canterbury, West Coast, South Canterbury and Southern DHBs, are more likely to be treated with chemotherapy, and in a timely manner, than other parts of the country.

Professor Lawrenson says that the timeliness of chemotherapy has become increasingly important in the management of bowel cancer, but that there are often other factors involved in how quickly someone receives treatment.

“The inequities we have seen in Māori and Pacific patients are not new. In this context, the disparity in treatment and timeliness may be partly due to the presence of other disease that means treatment with chemotherapy is not advised.

“While the use of chemotherapy has been increasing and the time taken to start chemotherapy has also been reducing, further work is needed to help understand the differences in treatment between patient groups.

“This may include more focus on health literacy to ensure patients understand the benefits (as well as the risks) of treatment. We also need to better understand the reasons for regional variation we have seen in this study,” says Professor Lawrenson.

This study has some limitations in that it does not include detailed clinical data on individual patients, and does not include any unfunded treatments that cancer patients may receive.


Latest stories

Related stories

Dr Jason Mika

Significant funding boost for University of Waikato research

The University of Waikato has achieved significant results in the latest funding round from the…

Jo Lane

Pharmacy to add to Waikato’s health offering

The University of Waikato intends to accept its first students in a new graduate-entry Master…

Te Huataki Waiora School of Health team Dr Ryan Paul, Dr Ross Lawrenson and Dr Rawiri Keenan

Waikato bolsters health leadership team

The University of Waikato has announced three key appointments to Te Huataki Waiora School of…

Neil Quigley and Kelvyn Eglinton

University of Waikato Medical School funding backed by Momentum Waikato

Funding for a Graduate School of Medicine at the University of Waikato will be supported…

Professor Holly Thorpe

Reimagining fields of play to grow the future of women in sport through world-class research

Waikato hosts global symposium to tackle issues from building gender-inclusive sporting environments to menstrual health…

Medical School Announcement

University of Waikato welcomes third medical school announcement

The University of Waikato welcomes the announcement by the National Party that if the Party…

Copyright Todd M. Henry 2020a

Kava based therapy for psychological trauma reaches clinical trial milestone

Waikato Pacific health researcher Dr Apo Aporosa has been awarded a Health Research Council grant…

Immunologist Dr William Kelton from the University of Waikato

Halve the herd without halving income with immune boosting milk

Imagine drinking a glass of milk to reduce your chances of picking up a nasty…

Dr Lynne Chepulis, Dr Ryan Paul

Prioritising Māori and Pacific patients for new diabetes drugs pays off

Prioritising Māori and Pacific patients in accessing two game-changing diabetes drugs is leading to better…

Dr Joanna Hicks

Health Research Council funding for gonorrhoea, and self-harm research

The Health Research Council of New Zealand (HRC) has announced funding for two University of…

Ross Lawrenson

Budget misses opportunity to train more NZ doctors

Today’s Budget misses an opportunity to invest in training more New Zealand doctors says Professor…

Exploring and embracing diversity

Research at the University of Waikato is helping to underpin policy development and decisions designed…